| Name | Title | Contact Details |
|---|
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Serve You is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kalypsys, Inc. is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Spokane Inter Res Tech Ins is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.